Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Completed 7Terminated 5Unknown 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 3Interventional 1

Sponsor

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 472Prostatic Neoplasms 420Neoplasms 379Multiple Myeloma 261Colorectal Neoplasms 261Lung Neoplasms 248Neoplasm Metastasis 230Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 190Pancreatic Neoplasms 181Squamous Cell Carcinoma of Head and Neck 163Recurrence 146Carcinoma, Renal Cell 144Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 134Stomach Neoplasms 129Triple Negative Breast Neoplasms 127Carcinoma, Hepatocellular 123Brain Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

belzutifan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × von Hippel-Lindau Disease × Clear all
NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡